-
Mashup Score: 9Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma - 2 month(s) ago
Objective Squalene epoxidase (SQLE) promotes metabolic dysfunction-associated steatohepatitis-associated hepatocellular carcinoma (MASH-HCC), but its role in modulating the tumour immune microenvironment in MASH-HCC remains unclear. Design We established hepatocyte-specific Sqle transgenic (tg) and knockout mice, which were subjected to a choline-deficient high-fat diet plus diethylnitrosamine to induce MASH-HCC. SQLE function was also determined in orthotopic and humanised mice. Immune landscape alterations of MASH-HCC mediated by SQLE were profiled by single-cell RNA sequencing and flow cytometry. Results Hepatocyte-specific Sqle tg mice exhibited a marked increase in MASH-HCC burden compared with wild-type littermates, together with decreased tumour-infiltrating functional IFN-γ+ and Granzyme B+ CD8+ T cells while enriching Arg-1+ myeloid-derived suppressor cells (MDSCs). Conversely, hepatocyte-specific Sqle knockout suppressed tumour growth with increased cytotoxic CD8+ T cells and
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 31Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments - 2 month(s) ago
Objective Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). Design We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with chronic liver disease without HCC were analysed. All samples were analysed for cell free DNA (cfDNA) concentration, and for mutations in TERT promoter, CTNNB1 , TP53 , PIK3CA and NFE2L2 by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples. Results In patients with active HCC, 40.2% of the ctDNA was mutated vs 14.6% in patients with inactive HCC and 1.8% in controls (p<0.001). In active HCC, we identified 27.5% of mutations in TERT promoter, 21.3% in TP53 , 13.1% in CTNNB1 , 0.4% in PIK3CA and 0.2% in NFE2L2, most of the times simi
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
#GUTImage from the paper by @campani_claudia et al "Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments" via https://t.co/Ew0p8jMp3N @Zucmanrossi @NaultJc #HCC https://t.co/Lbtfmsl2vI
-
-
Mashup Score: 31Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments - 2 month(s) ago
Objective Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). Design We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with chronic liver disease without HCC were analysed. All samples were analysed for cell free DNA (cfDNA) concentration, and for mutations in TERT promoter, CTNNB1 , TP53 , PIK3CA and NFE2L2 by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples. Results In patients with active HCC, 40.2% of the ctDNA was mutated vs 14.6% in patients with inactive HCC and 1.8% in controls (p<0.001). In active HCC, we identified 27.5% of mutations in TERT promoter, 21.3% in TP53 , 13.1% in CTNNB1 , 0.4% in PIK3CA and 0.2% in NFE2L2, most of the times simi
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
#GUTImage from the paper by @campani_claudia et al "Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments" via https://t.co/Ew0p8jMp3N @Zucmanrossi @NaultJc #HCC https://t.co/Lbtfmsl2vI
-
-
Mashup Score: 31Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments - 2 month(s) ago
Objective Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). Design We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with chronic liver disease without HCC were analysed. All samples were analysed for cell free DNA (cfDNA) concentration, and for mutations in TERT promoter, CTNNB1 , TP53 , PIK3CA and NFE2L2 by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples. Results In patients with active HCC, 40.2% of the ctDNA was mutated vs 14.6% in patients with inactive HCC and 1.8% in controls (p<0.001). In active HCC, we identified 27.5% of mutations in TERT promoter, 21.3% in TP53 , 13.1% in CTNNB1 , 0.4% in PIK3CA and 0.2% in NFE2L2, most of the times simi
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
#GUTImage from the paper by @campani_claudia et al "Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments" via https://t.co/Ew0p8jMp3N @Zucmanrossi @NaultJc #HCC https://t.co/Lbtfmsl2vI
-
-
Mashup Score: 33Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments - 2 month(s) ago
Objective Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). Design We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with chronic liver disease without HCC were analysed. All samples were analysed for cell free DNA (cfDNA) concentration, and for mutations in TERT promoter, CTNNB1 , TP53 , PIK3CA and NFE2L2 by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples. Results In patients with active HCC, 40.2% of the ctDNA was mutated vs 14.6% in patients with inactive HCC and 1.8% in controls (p<0.001). In active HCC, we identified 27.5% of mutations in TERT promoter, 21.3% in TP53 , 13.1% in CTNNB1 , 0.4% in PIK3CA and 0.2% in NFE2L2, most of the times simi
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
#GUTImage from the paper by @campani_claudia et al "Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments" via https://t.co/Ew0p8jMp3N @Zucmanrossi @NaultJc #HCC https://t.co/Lbtfmsl2vI
-
-
Mashup Score: 32Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments - 3 month(s) ago
Objective Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). Design We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with chronic liver disease without HCC were analysed. All samples were analysed for cell free DNA (cfDNA) concentration, and for mutations in TERT promoter, CTNNB1 , TP53 , PIK3CA and NFE2L2 by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples. Results In patients with active HCC, 40.2% of the ctDNA was mutated vs 14.6% in patients with inactive HCC and 1.8% in controls (p<0.001). In active HCC, we identified 27.5% of mutations in TERT promoter, 21.3% in TP53 , 13.1% in CTNNB1 , 0.4% in PIK3CA and 0.2% in NFE2L2, most of the times simi
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
#GUTImage from the paper by @campani_claudia et al "Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments" via https://t.co/Ew0p8jMp3N @Zucmanrossi @NaultJc #HCC https://t.co/Lbtfmsl2vI
-
-
Mashup Score: 25Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments - 3 month(s) ago
Objective Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). Design We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with chronic liver disease without HCC were analysed. All samples were analysed for cell free DNA (cfDNA) concentration, and for mutations in TERT promoter, CTNNB1 , TP53 , PIK3CA and NFE2L2 by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples. Results In patients with active HCC, 40.2% of the ctDNA was mutated vs 14.6% in patients with inactive HCC and 1.8% in controls (p<0.001). In active HCC, we identified 27.5% of mutations in TERT promoter, 21.3% in TP53 , 13.1% in CTNNB1 , 0.4% in PIK3CA and 0.2% in NFE2L2, most of the times simi
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
#GUTImage from the paper by @campani_claudia et al "Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments" via https://t.co/Ew0p8jMp3N @Zucmanrossi @NaultJc #HCC https://t.co/Lbtfmsl2vI
-
#GUTImage from the paper by Wen et al entitled "Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma" via https://t.co/BcyFloRLAJ #HCC https://t.co/PDWSM7MS5O